Follicular Lymphoma Grade 3 Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Follicular Lymphoma Grade 3 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 1

SynKIR-310 for Relapsed/Refractory B-NHL

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+21 more
Verismo Therapeutics18 enrolled5 locationsNCT06544265
Recruiting
Phase 1

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell LymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3B+3 more
Shanghai Exuma Biotechnology Ltd.18 enrolled1 locationNCT06830031
Recruiting

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd.49 enrolled5 locationsNCT05377307
Recruiting
Phase 1Phase 2

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd.49 enrolled5 locationsNCT05326243
Recruiting
Phase 1

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaB-cell Lymphoma+3 more
Washington University School of Medicine15 enrolled1 locationNCT05412290
Recruiting
Not Applicable

R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Diffuse Large B Cell LymphomaFollicular Lymphoma Grade 3B
oubai, MD/PhD64 enrolled1 locationNCT05040555